Baroreflex Activation Therapy in HFrEF Patients
JACC: Case Reports. 2026;31(23):108309.
Alexandra Bekiaridou, Kristie Coleman, Nhan Nguyen, Seth Wilks, Alfio Carroccio, Haisam Ismail, Marcin Kowalski, Miguel Alvarez Villela, Sirish Vullaganti, Theodoros Zanos, Stavros Zanos, Stavros Mountantonakis
Abstract
Background. Baroreflex activation therapy (BAT) may ameliorate autonomic imbalance in patients after heart failure with reduced ejection fraction (HFrEF); however, its effects on systemic inflammation and autonomic indices remain unknown.
Case summary. Seven patients with advanced HFrEF underwent BAT implantation. Three cases are presented in detail, illustrating distinct response patterns: clinical improvement, robust parasympathetic restoration, and anti-inflammatory response.
Discussion. After BAT, patients demonstrated improvements in quality of life, heart rate variability (HRV), and inflammatory biomarkers (tumor necrosis factor-α, interferon-γ). These preliminary findings suggest that BAT may exert therapeutic benefits through both autonomic restoration and anti-inflammatory modulation.
Take-home messages. An aggregate analysis of 7 patients with HFrEF who received BAT demonstrated favorable responses in inflammatory biomarkers, HRV, and clinical outcomes. BAT led to decrease in tumor necrosis factor-α and interferon-γ and autonomic balance restoration as measured by HRV. These findings support further investigation into the mechanisms of action of BAT.